Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$43.55 USD

43.55
2,417,000

+0.54 (1.26%)

Updated Sep 16, 2024 04:00 PM ET

After-Market: $43.55 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Inovio's Ebola Vaccine Positive in Expanded Phase I Study

Inovio Pharmaceuticals, Inc. (INO) recently reported positive preliminary results from the expanded stage of its phase I study, EBOV-001.

    Novartis (NVS) In-Licenses Ophthalmic Drug from Lubris LLC

    Novartis AG (NVS) recently announced that it has exercised an option to in-license ECF843 for ophthalmic indications worldwide from Lubris LLC.

      Novartis' Tafinlar, Mekinist Get EU Approval for NSCLC

      Novartis AG (NVS) recently announced that the European Commission has approved Tafinlar in combination with Mekinist for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC).

        GlaxoSmithKline Initiates Phase III Study with Mepolizumab

        GlaxoSmithKline plc (GSK) announced the initiation of a phase III study with Nucala (mepolizumab,) in patients with severe hypereosinophilic syndrome (HES).

          Mylan Receives CRL for Generic Advair Diskus From the FDA

          Mylan N.V. (MYL) recently suffered a huge setback when it received a complete response letter from the FDA regarding its ANDA for the generic version of asthma drug Advair Diskus.

            J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe

            Johnson & Johnson (JNJ) announced that the French health authority has granted approval to expand the label of Eprex to include treatment of symptomatic anaemia in patients with low or intermediate risk myelodysplastic syndromes (MDS).

              Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma

              Merck & Co., Inc. (MRK) recently announced that its anti-PD-1 therapy, Keytruda, has received positive opinion from CHMP for the treatment of patients with relapsed or refractory classical hodgkin lymphoma (cHL).

                Novartis' Acute Heart Failure Drug Fails in Late-Stage Study

                Novartis AG (NVS) recently suffered a setback on the announcement of disappointing data from a phase III study, RELAX-AHF-2, on pipeline candidate serelaxin (RLX030).

                  Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod

                  Allergan plc (AGN) announced yesterday that the FDA has approved its Juvederm Vollure XC dermal filler for correction of facial wrinkles and folds in adults over the age of 21.

                    6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017

                    Glaxo carries a Zacks Rank #2 (Buy).

                      Novartis (NVS) Announces Positive Data on Heart Failure Drug

                      Novartis AG (NVS) recently announced results of a new post-hoc analysis from the PARADIGM-HF study on heart failure drug Entresto.

                        AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal

                        London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for investigational drug ZS-9.

                          Arpita Dutt headshot

                          Why Biotech Stock Gilead (GILD) Could Be a Value Trap

                          Gilead's (GILD) valuation looks compelling but is the company really poised for

                            Kinjel Shah headshot

                            Glaxo Files for Label Expansion of Influenza Vaccine in US

                            GlaxoSmithKline plc (GSK) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA seeking approval to expand the label of Fluarix Quadrivalent ??? an influenza vaccine - for infants six months or older.

                              Merck's (MRK) Keytruda Gets FDA Nod for Lymphoma Indication

                              Merck & Co., Inc (MRK) announced that it has received FDA approval for Keytruda for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or who had relapsed after three or more prior lines of therapy.

                                The Zacks Analyst Blog Highlights: Intel, Glaxo, Schwab, Travelers and American Airlines

                                The Zacks Analyst Blog Highlights: Intel, Glaxo, Schwab, Travelers and American Airlines

                                  Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy

                                  Novartis AG (NVS) announced that the FDA has approved Kisqali, for use in combination with an aromatase inhibitor for the first-line treatment of postmenopausal women with hormone receptor positive, HR+/HER2- advanced or metastatic breast cancer.

                                    Alexion's sBLA for Soliris Receives FDA Acknowledgement

                                    Alexion Pharmaceuticals, Inc. (ALXN) announced that the FDA, on Mar 9, has accepted the supplemental Biologics License Application (sBLA) to expand the indication for Soliris

                                      Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus

                                      Epizyme, Inc. (EPZM) reported a loss of 60 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of 64 cents.

                                        Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4

                                        Agenus Inc. (AGEN) reported fourth-quarter 2016 loss of 30 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 33 cents but wider than the year-ago loss of 18 cents.

                                          Valeant (VRX) Issues Notes, Restructures Debt; Shares Down

                                          Valeant Pharmaceuticals International, Inc. (VRX) commenced an offer to purchase cash up to $600 million of aggregate principal amount due 2018.

                                            Aerie (AERI) Q4 Loss Widens, Rhopressa NDA Resubmitted

                                            Aerie Pharmaceuticals, Inc. (AERI) posted fourth-quarter 2016 loss of 87 cents per share (including stock-based compensation), wider than both the Zacks Consensus Estimate of a loss of 65 cents

                                              Novartis (NVS) Reports Positive Data on Biosimilar Humira

                                              Novartis AG (NVS) announced encouraging data for its proposed biosimilar verison of AbbVie's (ABBV) Humira.

                                                GlaxoSmithKline's Nucala Positive in Label Expansion Study

                                                GlaxoSmithKline plc. (GSK) announced that a phase IIIb study evaluating its respiratory drug Nucala (mepolizumab) met all its primary and secondary endpoints.

                                                  Impax (IPXL) Q4 Earnings in Line, Revenues Miss Estimates

                                                  Impax Laboratories Inc. (IPXL) posted fourth-quarter 2016 adjusted earnings of 16 cents per share, in line with the Zacks Consensus Estimate.